Legumes (pulses) and prostate cancer.

Prostate cancer risk: Data about the relation between legumes and total prostate cancer risk was provided by 4 cohort, including a total of 5,315 cases.
Significant protective effects were found in 3 out of 4 cohorts (Mills PK [1], Schuurman AG [10], Park SY [17]), including 5,179 cases. Questionnaires from 2 cohorts did not include soy (1, 10), and results from the third cohort were similar when soy products were excluded. No association was found in the remaining cohort, which was of very small size (Tseng M [13]). The average RR = 0.86 (excluding incomplete data from Tseng M [13]).

Inclusion of intermediate levels of consumption:
The figure below shows RR from 2 cohorts including a total of 5,010 cases (94% of cases from all cohorts combined). Results from one cohort could not be included since they were presented in frequency of use (1):
Protective effects could be found at the level of consumption of > 62g/day (Schuurman AG), and > 71 g/day (Park SY).

RRs for the association between total legumes and total prostate cancer risk (g/day):



Advanced prostate cancer risk: Data about the relation with advanced stage prostate cancer risk was provided by 2 cohorts.
A significant protective effect against nonlocalized/high grade disease was found in the largest cohort (17), but no association was found with poorly/undifferentiated cancer in the other cohort (10).
Prostate cancer mortality: Data about the relation with prostate cancer mortality was provided by 3 cohorts (5, 20, 22). No associations were found.

Conclusion: Significant protective effects of legumes against total prostate cancer risk were found in 3 cohorts of moderate-large size and including 97% of all cases. No other associations were found. Legumes possibly protect against total prostate cancer risk (- 14%). This effect could be found at the level of consumption of > 71 g/day.
No evidence was found for an association between legumes and advanced prostate cancer risk or mortality. This evidence did not change when advanced cancer and mortality were considered one end point.

| More information: back to literature review.|